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 Abstract 
Objectives: The purpose of this study is to examine clinical and pathological 
features, treatment modality approaches in the elderly, especially in patients 
aged 80 years and older. 
Methods: From the databases at two educational hospitals during the period 
from January 1978 and December 2007, medical records of lung cancer 
patients were retrospectively reviewed. The patient population was divided 
into three age groups: less than 70 years (the <70 age group), 70–79 years 
(the 70–79 age group), and 80 years or older (the ≥80 age group). Time 
trends were also studied in two-time intervals: first study period up to 1997, 
which represents past practice standards, the second study period up to 2007, 
which represents contemporary practice. 
Results: Patients aged 80 years and older comprised 7.5% of 2775 
consecutive patients with lung cancer, and there was a rapid increase in the 
proportion of patients aged 80 years or older from the earlier to the later 
time period. The ≥80 age group had higher proportion of poor performance 
status (PS) and comorbid disease than the <70 age group and the 70–79 age 
group. Unchanged proportion of patients with poor PS and advanced disease 
at presentation were observed in the ≥80 age group. The ≥80 age group was 
less likely to be subjected to surgery or chemotherapy, and had inferior 
outcomes when compared with the 70–79 age group and the <70 age group. 
Survival improvement was not observed in the ≥80 age group. Multivariate 
analysis showed good PS, early clinical stage and surgery were favorable 
prognostic factors in the ≥80 age group. 
Conclusion: In order to improve the outcome, detection of early stage lung 
cancer in patients with good PS and thorough pretreatment evaluation for 
appropriate treatment are indeed essential even for the ≥80 age group of 
patients. 
 
 1. Introduction 
In developed countries, populations are becoming older and the elderly have 
a higher incidence of malignant diseases. Among malignant diseases, the 
incidence and mortality of lung cancer has increased worldwide during the 
last few decades [1,2]. The majority of cases of lung cancer diagnosed were 
those between the ages of 50 and 80 years, as a result there is little data 
relating to the clinical characteristics, disease status, treatment modality, 
and survival of patients aged 80 years and over [3–5]. Too few patients older 
than 80 years were included in previous clinical trials to make any 
conclusions regarding this age group, therefore, additional studies 
specifically focusing on these elderly patients are required. With recent 
improvements in the medical management of lung cancer, the availability of 
many new drugs, and a better standard of medical care and more widespread 
health services, survival in these elderly patients might have changed. Very 
recently, Owonikoko et al. analyzed the outcomes for lung cancer in the very 
elderly using the national Surveillance, Epidemiology, and End Results 
Database (SEER) in U.S.A. [6]. Nevertheless, there was a lack of information 
on the impact of performance status (PS: ECOG), comorbid disease, and 
chemotherapy on survival outcomes. To address the question of whether the 
overall survival of lung cancer patients 80 years of age or older has improved, 
therefore, we here reviewed retrospectively the clinical data from the 
consecutive patients with lung cancer diagnosed at our two tertiary hospitals 
to assess the incidence and outcome of lung cancer in the very elderly. We 
also focused on the role of PS, comorbid disease and treatment modalities 
including chemotherapy on survival of the elderly patients aged 80 years or 
over. 
 
2. Patients and methods 
Clinicopathological data for all the consecutive patients with lung cancer 
were obtained by retrospective review from the databases at University of 
Tsukuba Hospital or Tsukuba Medical Center Hospital and Regional Cancer 
Center. The patients were diagnosed pathologically and treated between 
January 1978 and December 2007 at these two tertiary hospitals. 
Pathological diagnosis was defined by the WHO classification [7]. Staging 
was recorded for patients with non-small cell lung cancer (NSCLC) according 
to TNM classification [8] and those with small cell lung cancer (SCLC) 
according to limited disease/extensive disease classification. Demographic 
data, including age, gender, and PS, were retrieved from the medical records 
of them along with the specific details of the cancer. We evaluated the 
number of comorbid disease and seriousness of comorbid disease using 
Charlson index (CI) score [9]. This study was approved by the Institutional 
Ethics Committee of each hospital. According to the recent studies on 
outcomes in octogenarians, the entire patient population was divided into 
three age groups: less than 70 years (the <70 age group), 70–79 years (the 
70–79 age group), and 80 years or older (the≥80 age group) at diagnosis [6,10]. 
The median survival time (MST) was compared among the three age groups 
as defined by gender, histologic subtype, stage, and therapy. Two predefined 
time periods, that is patients presenting between 1978 and 1997 and 
between 1998 and 2007 was used for comparison of survival. The year 1998 
was chosen as a cutoff point because of two reasons. One reason was third 
generation cytotoxic agents such as taxanes, gemcitabine, vinorelbine, and 
irinotecan were introduced around this time to treat both NSCLC and SCLC 
patients. Another reason was a very large-scale study using SEER database, 
which included 316,682 patients, by Owonikoko et al. chose this year as a 
cutoff point [6]. Differences of distribution of subpopulations between each 
period were analyzed using a Chi-square test. The Kaplan–Meier method 
was used to assess survival curves and the log-rank test to evaluate the 
statistical significance of differences between the two groups [11,12]. The 
length of survival was defined as the interval in months from the date of the 
initial therapy or supportive care until the date of deaths or the date of last 
follow-up. The Cox proportional hazard model was used to study the effects 
of age on survival while adjusting for other important factors. All statistical 
analysis were performed using SPSS 10.1 for Windows (SPSS Inc., Chicaco, 
IL, USA) and a probability value less than 0.05 was considered to be 
significant. 
 3. Results 
3.1. Demographics 
A total of 2775 patients with lung cancer were registered during the 31-year 
period; 209 patients (7.5%) were 80 years or older (median, 82 years), 
37.6%were 70–79 years (median, 74 years), and 54.9% of patients were 
younger than 70 years (median, 62 years) (Table 1). Men constituted 
approximately 76.1%, and distribution was comparable among the three age 
groups (Table 1). Poor PS (2–4) accounted for 15.3% in the <70 age group, 
18.8% in the 70–79 age group and 45.0% in the ≥80 age group. 49.3% of the 
209 elderly patients had two or more comorbid disease. Poor PS, number of 
comorbid disease, and number of CI in the ≥80 age group were significantly 
higher than those in other two control groups of patients (Table 1). 
3.2. Histology and staging 
NSCLC accounted for 87.6% in the <70 age group, 84.9% in the 70–79 age 
group and 89.0% in the 80 age group. Adenocarcinoma and squamous cell 
histology represented approximately 40–50% and 20–30% of patients in each 
of the three age groups (Table 1). In NSCLC patients, stage distribution at 
the time of diagnosis was similar for the three groups; stages IIIB or IV 
represented approximately half of patients in each of the three groups (Table 
2). In SCLC patients, extensive disease at the time of diagnosis was similar 
for the three age groups; extensive disease represented more than half of 
patients in each of the three groups (Table 2). 
3.3. Initial therapy for NSCLC and SCLC 
In NSCLC, overall, 50.7%, 44.9%, and 18.3% of the <70 age group, the 70–79 
age group, and the 80 age group, respectively, received surgery; 6.0%, 13.8%, 
and 30.6%, respectively, received radiation; and 32.1%, 22.1%, and 5.9%, 
respectively, received chemotherapy. In contrast, 11.2% of the <70 age group, 
19.2% of the 70–79 age group, and 45.2% of the 80 age group received 
supportive care (Table 2). In SCLC, overall, 83.1%, 83.5%, and 73.9% of the 
<70 age group, the 70–79 age group, and the 80 age group, respectively, 
received chemotherapy. In contrast, 5.3% of the <70 age group, 8.9% of the 70
–79 age group, and 21.7% of the 80 age group received supportive care only 
(Table 2). 
3.4. Survival 
In overall lung cancer, MST was 21months for the <70 age group, 18 months 
for the 70–79 age group, and 12 months for the 80 age group. Similarly, the 
80 age group had the worst outcome among both men and women; MST were 
9 and 14 months in men and women, respectively, compare with 18 and 20 
months, respectively, in the <70 age group (Table 3). In NSCLC, analysis by 
stage demonstrated the lowest survival rates in the 80 age group (Table 3). 
Table 4 shows survival analysis based on treatment modality. In NSCLC 
patients who received chemotherapy, the 80 age group had a worse survival 
than the <70 age group (Table 4). In SCLC, overall MST was 13 months for 
the <70 age group, 9 months for the 70–79 age group, and 9 months in the 80 
age group. In overall SCLC patients, the 80 age group had poorer survival 
than the <70 age group (Table 3). 
3.5. Temporal trend analysis 
The 80 age group constituted a higher proportion of total patient cases (9.9%) 
in the more recent period, 1998–2007, compared with the earlier period of 
1978–1997, in which they made up 4.4% (Table 1). The proportion of the 70–
79 age group in the earlier and later time periods was 33.7% and 40.5%, 
respectively (Table 1). In the 80 age group, there were no changes in 
proportion of patients with poor PS, number of comorbid disease 2, number 
of CI 2 between the earlier and later time periods. On the other hand, there 
were significant increases in good PS (PS: 0–1) in the <70 age group and 
the 70–79 age group (Table 1). In NSCLC, there was no significant change in 
the stage distribution across the three age groups, and no trend toward 
increased use of radiation or chemotherapy was observed (Table 2). There 
seemed to be increased use of surgery in the 80 age group between the two 
time periods, but it did not reach statistical significant difference (Table 2) (p 
= 0.1866). The survival pattern was similar during both time periods; the 
<70 age group had the best outcome, followed by the 70–79 age group and 
then the 80 age group (Table 3). In NSCLC, except for the 80 age group, there 
was a trend of better overall survival in the recent period, 1998–2007 for the 
<70 age group and the 70–79 age group (Table 3). With regard to treatment 
modality for NSCLC, there was a substantial improvement in disease 
outcome for the <70 age group and the 70–79 age group with surgery, that for 
septuagenarians with radiation, and that for the <70 age group with 
chemotherapy, but the improvement was not observed in the 80 age group 
with any treatment (Table 4). In SCLC, overall, there was not a trend of 
better overall survival in the recent period for any three age groups (Table 3). 
However, there was a substantial improvement in disease outcome for the 
<70 age group with chemotherapy, but the improvement was not observed in 
the 70–79 age group and the 80 age group (Table 4). 
3.6. Multivariate analysis 
Table 5 summarizes the relationship between clinical variables and survival. 
In univariate analysis, age less than 80 years old, female gender, NSCLC, 
good PS, early clinical stage, number of comorbid disease, CI, and surgical 
treatment were statistically significant favorable prognostic factors. 
According to a multivariate Cox proportional hazards model, female gender, 
good PS, early clinical stage and surgery showed a statistical significance in 
survival. But number of comorbid disease, CI revealed no statistical 
significance in survival. Same analysis included only the ≥80 age group 
revealed good PS (p = 0.001, 95% confidence interval: 1.642–4.184), early 
clinical stage (p = 0.001, 95% confidence interval: 1.843–5.195), and surgical 
treatment (p = 0.004, 95% confidence interval: 1.561–10.70) were 
statistically significant favorable prognostic factors. 
 4. Discussion 
There has been an increasing interest in the treatment of elderly patients 
with lung cancer [5,6,10,13–31].However, clinical information regarding lung 
cancer patients aged 80 years and over has not been fully available since 
such patients are not usually included in clinical trials and retrospective 
care analysis. Therefore, there is a great amount of scientific uncertainty 
regarding the risks and benefits of lung cancer treatment in patients aged 80 
and older. Using the SEER database, Owonikoko et al. studied the burden 
and outcome of lung cancer in the elderly, particularly for patients aged 80 
years and older [6]. Nevertheless, there was a lack of information on the 
impact of PS, comorbid disease, and chemotherapy on survival outcomes. We 
here reviewed retrospectively the clinical data from the consecutive patients 
with lung cancer diagnosed at our two tertiary hospitals to assess the 
incidence and outcome of lung cancer in the very elderly. According to the 
same analyses as previous studies [6,10], this study characterized lung 
cancer presentation and outcome in the very elderly patient population and 
compared it with that of septuagenarians and with the younger patient 
population. It is noteworthy that the ≥80 age group account for 7.5% of all 
lung cancers. This proportion was lower than 14% of the study by Owonikoko 
et al. [6], but there was a rapid increase in the proportion of the ≥80 age 
group from the earlier to the later time period. The ≥80 age group had 
higher proportion of patients with poor PS, and presence of severe comorbid 
disease than those in septuagenarians and patients younger than 70 years of 
age. In addition, there was unchanged proportion of patients with poor PS 
and advanced disease at presentation aged 80 years or older. Aging is 
associated with a high prevalence of comorbid diseases [17,18,27,31]. 
Particularly those patients with a long smoking history are predisposed to 
comorbid diseases such as chronic obstructive pulmonary disease and 
cardiovascular disease, as well as other smoking-related malignancies [19]. 
Findlay et al. reported the incidence of these comorbid diseases in patients 
with SCLC over the age of 70 years [19], which was almost same incidence as 
our results. The univariate analysis showed a significant association of 
number and severity of comorbid disease with a survival in our series of 
older patients. However, they were not confirmed in the multivariate 
analysis. Several factors may account for the lower prognostic relevance of 
number and severity of comorbid diseases after 80 years of age. The patients 
aged 80 years or older might undergo a strict selection process before being 
scheduled for correct diagnosis of lung cancer [6,17,18]. Correct diagnosis of 
lung cancer is established by pathological specimens, which are usually 
obtained via transbronchial or transthoracic approach. Elderly patients with 
severe comorbid disease may be excluded in these processes of correct 
diagnosis. A frequent reason for withholding invasive diagnostic procedures 
from elderly patients with severe comorbid disease are the fears of 
complications, which can be a genuine, but not always justified, concern. 
Breen et al. showed the presence of comorbid condition (CI≥6) tended to be 
associated with poor survival in NSCLC patients, which was inconsistent 
with our results [31]. In their study, 41.2% of the elderly patients had CI ≥6, 
but there were only 5 of 209 patients with CI ≥6 in our study. Low frequency 
of severe comorbid disease in our elderly patients might influence on the 
results of multivariate analysis. The ≥80 age group was less likely to be 
subjected to surgery or chemotherapy, and had inferior outcomes when 
compared with the 70–79 age group and the <70 age group. A previous 
analysis of the linked SEER-Medicare database of patients with lung cancer 
who were older than 65 years and diagnosed between 1994 and 1999 
revealed that elderly patients older than 75 years were less likely to receive 
chemotherapy [32]. Owonikoko et al. observed a consistent trend of lower 
rates of surgery and radiation therapy with increased age, whereby more 
than 80% of the younger population received this active therapy compared 
with 70% of septuagenarians and with only 50% of the very elderly [6]. But 
their analysis could not address all forms of therapy, especially 
chemotherapy. Our results were consistent with these large scale studies. It 
is a debatable question of whether the elderly patients will do as well as 
younger patients when standard therapy is administered for their stage of 
disease. Majority of elderly patients have been denied potentially beneficial 
treatment and participation in clinical trials solely because of chronological 
age and because of the physician perception that they are too frail to 
withstand treatment [24,25]. On the contrary, the benefit of standard 
therapy is well demonstrated in the elderly population in general and is 
comparable to the benefit obtained by younger patients [22–24,26]. In a 
SEER-Medicine database study, the ≥80 age group had worse survival 
outcomes than the 70–79 age group and the <70 age group. Our results in 
both genders were consistent with this large scale study. O’Brien et al. 
recently reported the trends in the chemotherapeutic outcome in patients 
age ≥70 years with SCLC and NSCLC [14,15]. There was no improvement in 
survival in their NSCLC patients. On the other hand, there was a significant 
improvement in survival for elderly SCLC patients treated by chemotherapy 
in the past 20 years [14,15]. Their study included only 26 (8.0%) of 322 
patients aged 80 years and over and the MST in the former study period was 
too short to compare. In the analysis by Owonikoko et al., there was a trend 
of better overall survival during 1998–2003 for all age groups, although they 
noted no substantial change in stage distribution of disease across these time 
periods [6]. As Owonikoko et al. suggested, the improved survival in the 
more recent period may also be a reflection of better supportive care 
measures or merely a function of stage migration resulting from advanced 
imaging modalities [6].We showed a trend of better overall survival only for 
the 70–79 age group and the <70 age group. There was an inconsistence 
between their results and ours. Survival improvement in our patients might 
be associated with improvement in radiotherapy for the 70–79 age group, 
and that chemotherapy for the <70 age group, and that in surgery for these 
age groups. Although we do not know why we did not show any trend of 
better survival for the 80 age group, we speculate that chronological age, 
unchanged high proportion of poor PS and advanced disease at presentation 
might be the reasons for which influenced on the outcome. In addition to 
them, physician’s and patient’s belief of shorter life expectancy in the elderly 
and increased adverse effect of intensive treatment might influence on the 
treatment selection and prognosis of the aged patients [20,21]. 
It has been generally accepted that female, good PS, early clinical stage, 
surgical resection are favorable prognostic factors in the all lung cancer 
patients [4,13,33]. Asmis et al. reported that comorbid condition (Charlson 
index ≥1) was associated with poor survival [13]. They used clinical data in 
1255 NSCLC patients, who were enrolled in prospective randomized trials of 
systemic chemotherapy in Canada [13]. On the other hand, Coebergh et al. 
showed gender and number of comorbid disease had no prognostic effect 
using a cancer registry records data on 4072 NSCLC patients in The 
Netherlands [33]. Our multivariate analysis showed that female, good PS, 
early clinical stage, surgical resection are favorable prognostic factors in the 
all lung cancer patients. In ≥80 age group, however, female and comorbidity 
(number of comorbid disease ≤1, number of Charlson index ≤1) were not 
favorable prognostic factors, which were consistent with that by Coebergh et 
al. [33]. We do not know the exact reason why they were not prognostic 
factors in our patients aged 80 years or over, but we speculate that difference 
in study population and that in index studied (ex. number of comorbid 
disease and number of Charlson index) might influence on these results. Our 
study suffers from limitations imposed by its retrospective nature and 
limited number of patients, but we suppose that it is important to report 
clinicopathological features and outcome of lung cancer in the very elderly. 
The ≥80 age group account for 7.5% of all lung cancers, were increased 
rapidly. They were less likely to be subjected to surgery or chemotherapy, 
compared with the 70–79 age group and the <70 age group. In order to 
improve the outcome, detection of early stage lung cancer and thorough 
pretreatment evaluation for appropriate treatment is indeed essential even 
for the≥80 age group of patients.  
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Table 1. Characteristics of lung cancer patients 80 years  
and over 
                                                                       
No. of patients 209 
 
Gender M : F   145 : 64 
 
Age(year) median 82, range 80-94 
 
Performance status 
 0-1 115 
 2-4 94 
 
Histology  
 Adenocarcinoma 102 
 Squamous cell carcinoma 76 
 Large cell carcinoma 7 
 Others 1 
 Small cell carcinoma 23 
 
Clinical stage 
 IA-B 52 
 IIA-B 15 
 IIIA 15 
 IIIB 60 
 IV 67 
 
Comorbid diseases  
 Hypertention 65 
 Cardiovascular 62 
 Pulmonary 49 
 Cerebrovascular 29 
 Diabetes 24 
 Malignant 24 





Table 2. Uni- and multi-variate analyses of prognostic factors in elderly patients with lung 
cancer 
 
      Uni-variate analysis  Multi-variate analysis 
 Factors (logrank test) (Cox`s proportional hazard model) 
  p-value      hazard ratio 95%CI p-value 
 
 
Age(80-84, 85≥) 0.0270 1.681 1.056 - 2.677 0.029 
Gender(female, male) 0.0967 0.958 0.596 – 1.542 0.861 
Pathology(NSCLC, SCLC) 0.0163 1.435 0.781 – 2.639 0.245 
Performance status(0-1, 2-4) 0.0001 2.621 1.642 – 4.184 0.001 
Stage(IA-IIIA, IIIB-IV) 0.0001 3.094 1.843 – 5.195 0.001 
No. of comorbid disease(0-1, 2≥) 0.0090 1.404 0.851 – 2.315 0.184 
Charlson index score(0, 1≥) 0.0030 1.064 0.600 – 1.888 0.831 
Treatment(surgery, others) 0.0001 4.090 1.561 – 10.70 0.004 
 
 





Table 3. Trends in gender, performance status, and stage according to period at diagnosis 
 
   NSCLC   SCLC 
  1978-1990 1991-2000 2001-2007 1978-1990 1991-2000 2001-2007 
 
No.of patients 27 40 119 5 2 16 
Gender 
 M 18(66.7%) 29(72.5%) 77(64.7%) 5(100%) 2(100%) 14(87.5%) 
 F 9(33.3%) 11(27.5%) 42(35.3%) 0(0%) 0(0%) 2(12.5%) 
Performance status 
 0-1 16(59.3%) 25(62.5%) 62(52.1%) 2(40.0%) 1(50.0%) 9(56.3%) 
 2-4 11(40.7%) 15(37.5%) 57(47.9%) 3(60.0%) 1(50.0%) 7(43.8%) 
Stage 
 IA-IIIA 10(37.0%) 20(50.0%) 51(42.9%) 
 IIIB 10(37.0%) 11(27.5%) 32(26.9%) 







Table 4. Trends in treatment modalities according to period at diagnosis 
 
   NSCLC   SCLC 
  1978-1990 1991-2000 2001-2007 1978-1990 1991-2000 2001-2007 
 
No.of patients 27 40 119 5 2 16 
 
Treatment modalities 
 Surgery 1(3.7%)* 6(15.0%) 27(22.7%) 0(0%) 0(0%) 0(0%) 
 Radiotherapy 11(40.7%)# 13(32.5%) 33(27.7%)# 0(0%) 0(0%) 1(6.3%) 
 Chemotherapy 3(11.1%)** 0(0%) 8(6.7%)** 5(100%) 2(100%) 10(62.5%) 
 Supportive Care 12(44.4%) 21(52.5%) 51(42.9%) 0(0%) 0(0%) 5(31.3%) 
 
 
*p=0.0279   **p=0.4271   #p=0.2477 
 
Table 5. Survival in lung cancer according to period at diagnosis 
 
   NSCLC   SCLC 
  1978-1990 1991-2000 2001-2007 1978-1990 1991-2000 2001-2007 
 
No.of patients 27 40 119 5 2 16 
 
MST(Mo) 12 16 14 8 6 9 
 
1-year survival 9(33.3%) 12(30.0%) 38(31.9%) 2(40.0%) 0(0%) 2(12.5%) 
 
2-year survival 3(11.1%) 9(22.5%) 20(16.8%) 0(0%) 0(0%) 0(0%) 
 
3-year survival 2(7.4%) 5(12.5%) 9(7.6%) 0(0%) 0(0%) 0(0%) 
 
 
  p=0.2088 p=0.7418 p=0.7015 p=0.4984 
  
  p=0.3633 p=0.8455 
 
NSCLC : Non-small cell lung cancer 
SCLC : Small cell lung cancer 
MST : Median survival time 
